$UTHR
UNITED THERAPEUTICS Corp Stock $uthr

$uthr Overview Financials Valuation SEC Filings Company Website

2020 Form 10-K Financial Statement

#000108255421000008 Filed on February 24, 2021

Income Statement

Concept	2020	2019 Q4	2019
Revenue	$1.483B	$311.1M	$1.449B
YoY Change	2.38%	-18.43%	-11.0%
Cost Of Revenue	$108.1M	$28.80M	$117.6M
YoY Change	-8.08%	-9.72%	-40.82%
Gross Profit	$1.375B	$282.3M	$1.331B
YoY Change	3.31%	-19.23%	-6.85%
Gross Profit Margin	92.71%	90.74%	91.88%
Selling, General & Admin	$423.9M	$105.2M	$336.2M
YoY Change	26.09%	32.83%	26.49%
% of Gross Profit	30.82%	37.27%	25.26%
Research & Development	$357.7M	$113.6M	$1.183B
YoY Change	-69.75%	-18.16%	230.43%
% of Gross Profit	26.01%	40.24%	88.84%
Depreciation & Amortization	$49.90M	$12.50M	$45.90M
YoY Change	8.71%	19.05%	27.86%
% of Gross Profit	3.63%	4.43%	3.45%
Operating Expenses	$357.7M	$218.8M	$1.183B
YoY Change	-69.75%	0.37%	230.43%
Operating Profit	$593.6M	$63.50M	-$187.6M
YoY Change	-416.42%	-51.71%	-123.29%
Interest Expense	$23.50M	$3.400M	$44.20M
YoY Change	-46.83%	-22.73%	217.99%
% of Operating Profit	3.96%	5.35%
Other Income/Expense, Net	$45.30M	$1.400M	$22.60M
YoY Change	100.44%	-148.28%	-148.6%
Pretax Income	$638.9M	$68.30M	-$165.0M
YoY Change	-487.21%	-25.68%	-121.74%
Income Tax	$124.1M	$15.70M	-$60.50M
% Of Pretax Income	19.42%	22.99%
Net Earnings	$514.8M	$52.60M	-$104.5M
YoY Change	-592.63%	-19.45%	-117.74%
Net Earnings / Revenue	34.71%	16.91%	-7.21%
Basic Earnings Per Share	$11.65	$1.20	-$2.39
Diluted Earnings Per Share	$11.54	$1.20	-$2.39
COMMON SHARES
Basic Shares Outstanding	44.20M shares	43.88M	43.80M shares
Diluted Shares Outstanding	44.60M shares		43.80M shares

Balance Sheet

Concept	2020	2019 Q4	2019
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.835B	$1.486B	$1.486B
YoY Change	23.49%	4.94%	4.94%
Cash & Equivalents	$738.7M	$738.4M	$738.4M
Short-Term Investments	$1.096B	$747.5M	$747.5M
Other Short-Term Assets	$88.30M	$133.8M	$133.8M
YoY Change	-34.01%	77.45%	77.45%
Inventory	$86.50M	$93.40M	$93.40M
Prepaid Expenses
Receivables	$157.4M	$151.4M	$151.4M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$2.167B	$1.865B	$1.865B
YoY Change	16.23%	5.46%	5.46%
LONG-TERM ASSETS
Property, Plant & Equipment	$731.6M	$738.5M	$743.3M
YoY Change	-1.57%	5.55%	6.23%
Goodwill		$28.00M
YoY Change		-11.11%
Intangibles
YoY Change
Long-Term Investments	$1.150B	$767.5M	$767.5M
YoY Change	49.79%	73.41%	73.41%
Other Assets	$408.5M	$154.6M	$379.8M
YoY Change	7.56%	-31.04%	18.72%
Total Long-Term Assets	$2.448B	$2.049B	$2.049B
YoY Change	19.47%	25.47%	25.47%
TOTAL ASSETS
Total Short-Term Assets	$2.167B	$1.865B	$1.865B
Total Long-Term Assets	$2.448B	$2.049B	$2.049B
Total Assets	$4.615B	$3.913B	$3.913B
YoY Change	17.93%	15.07%	15.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.100M	$9.900M	$9.900M
YoY Change	-58.59%	-57.14%	-57.14%
Accrued Expenses	$182.9M	$138.5M	$140.3M
YoY Change	30.36%	-3.15%	-1.89%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$250.0M	$250.0M
YoY Change	-100.0%
Total Short-Term Liabilities	$323.3M	$463.0M	$463.0M
YoY Change	-30.17%	67.39%	67.39%
LONG-TERM LIABILITIES
Long-Term Debt	$800.0M	$600.0M	$600.0M
YoY Change	33.33%	140.0%	140.0%
Other Long-Term Liabilities	$96.50M	$70.00M	$70.00M
YoY Change	37.86%	5.11%	5.11%
Total Long-Term Liabilities	$896.5M	$70.00M	$670.0M
YoY Change	33.81%	5.11%	111.62%
TOTAL LIABILITIES
Total Short-Term Liabilities	$323.3M	$463.0M	$463.0M
Total Long-Term Liabilities	$896.5M	$70.00M	$670.0M
Total Liabilities	$1.220B	$1.133B	$1.133B
YoY Change	7.66%	91.0%	91.0%
SHAREHOLDERS EQUITY
Retained Earnings		$3.325B
YoY Change		-3.19%
Common Stock		$2.049B
YoY Change		5.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.395B	$2.780B	$2.780B
YoY Change
Total Liabilities & Shareholders Equity	$4.615B	$3.913B	$3.913B
YoY Change	17.93%	15.07%	15.07%

Cashflow Statement

Concept	2020	2019 Q4	2019
OPERATING ACTIVITIES
Net Income	$514.8M	$52.60M	-$104.5M
YoY Change	-592.63%	-19.45%	-117.74%
Depreciation, Depletion And Amortization	$49.90M	$12.50M	$45.90M
YoY Change	8.71%	19.05%	27.86%
Cash From Operating Activities	$755.7M	$102.5M	-$206.6M
YoY Change	-465.78%	20.02%	-126.54%
INVESTING ACTIVITIES
Capital Expenditures	$59.30M	-$24.70M	$83.70M
YoY Change	-29.15%	-52.32%	-54.61%
Acquisitions	$0.00		$0.00
YoY Change			-100.0%
Other Investing Activities	-$679.2M	$90.90M	-$251.7M
YoY Change	169.85%	-545.59%	-60.44%
Cash From Investing Activities	-$738.5M	$66.20M	-$335.4M
YoY Change	120.18%	-191.69%	-59.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$16.90M	-150.0M	$611.2M
YoY Change	-102.77%	-150100.0%	9601.59%
NET CHANGE
Cash From Operating Activities	$755.7M	102.5M	-$206.6M
Cash From Investing Activities	-$738.5M	66.20M	-$335.4M
Cash From Financing Activities	-$16.90M	-150.0M	$611.2M
Net Change In Cash	$300.0K	18.70M	$69.20M
YoY Change	-99.57%	40.6%	-292.76%
FREE CASH FLOW
Cash From Operating Activities	$755.7M	$102.5M	-$206.6M
Capital Expenditures	$59.30M	-$24.70M	$83.70M
Free Cash Flow	$696.4M	$127.2M	-$290.3M
YoY Change	-339.89%	-7.29%	-148.87%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001082554
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	us-gaap:ProductMember
CY2019	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	us-gaap:ProductMember
CY2018	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	us-gaap:ProductMember
CY2020	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	us-gaap:ProductMember
CY2019	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	us-gaap:ProductMember
CY2018	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	us-gaap:ProductMember
CY2019	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	us-gaap:AccountingStandardsUpdate201613Member
CY2020	uthr	Defined Contribution Plan Annual Increments DefinedContributionPlanAnnualIncrements	0.33
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Entity File Number EntityFileNumber	0-26301
CY2020	dei	Entity Registrant Name EntityRegistrantName	United Therapeutics Corporation
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	52-1984749
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	1040 Spring Street,
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Silver Spring,
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20910
CY2020	dei	City Area Code CityAreaCode	(301)
CY2020	dei	Local Phone Number LocalPhoneNumber	608-9292
CY2020	dei	Security12b Title Security12bTitle	Common Stock, par value $.01 per share
CY2020	dei	Trading Symbol TradingSymbol	UTHR
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Small Business EntitySmallBusiness	false
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2020	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	4726041837	USD
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	44544335	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	738700000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	738400000	USD
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1096300000	USD
CY2019Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	747500000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	157400000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	93400000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	151400000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	86500000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	88300000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	133800000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	2167200000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	1864500000	USD
CY2020Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	1149600000	USD
CY2019Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	767500000	USD
CY2020Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	158100000	USD
CY2019Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	158300000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	731600000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	738500000	USD
CY2020Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	238600000	USD
CY2019Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	230000000.0	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	169900000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	154600000	USD
CY2020Q4	us-gaap	Assets Assets	4615000000.0	USD
CY2019Q4	us-gaap	Assets Assets	3913400000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	187000000.0	USD
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	148400000	USD
CY2020Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	0	USD
CY2019Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	250000000.0	USD
CY2020Q4	uthr	Share Tracking Award Plans ShareTrackingAwardPlans	96800000	USD
CY2019Q4	uthr	Share Tracking Award Plans ShareTrackingAwardPlans	25000000.0	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	39500000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	39600000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	323300000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	463000000.0	USD
CY2020Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	800000000.0	USD
CY2019Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	600000000.0	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	96500000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	70000000.0	USD
CY2020Q4	us-gaap	Liabilities Liabilities	1219800000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	1133000000.0	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	245000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	245000000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	71126314	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70503775	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44507098	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43884559	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	700000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	700000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2148700000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2047900000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-14200000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-14200000	USD
CY2019Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	26619216	shares
CY2020Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	26619216	shares
CY2020Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	2579200000	USD
CY2019Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	2579200000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	3839200000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	3325200000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	3395200000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	2780400000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4615000000.0	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3913400000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1483300000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1448800000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1627800000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	108100000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	117600000	USD
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	198700000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	357700000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1182600000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	357900000	USD
CY2020	uthr	Selling General And Administrative Expense And Adjustments SellingGeneralAndAdministrativeExpenseAndAdjustments	423900000	USD
CY2019	uthr	Selling General And Administrative Expense And Adjustments SellingGeneralAndAdministrativeExpenseAndAdjustments	336200000	USD
CY2018	uthr	Selling General And Administrative Expense And Adjustments SellingGeneralAndAdministrativeExpenseAndAdjustments	265800000	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	889700000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	1636400000	USD
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	822400000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	593600000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-187600000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	805400000	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	28600000	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	44200000	USD
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	28600000	USD
CY2020	us-gaap	Interest Expense InterestExpense	23500000	USD
CY2019	us-gaap	Interest Expense InterestExpense	44200000	USD
CY2018	us-gaap	Interest Expense InterestExpense	13900000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	49300000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	22600000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7700000	USD
CY2020	uthr	Impairment Of Investments In Privately Held Companies ImpairmentOfInvestmentsInPrivatelyHeldCompanies	9100000	USD
CY2019	uthr	Impairment Of Investments In Privately Held Companies ImpairmentOfInvestmentsInPrivatelyHeldCompanies	0	USD
CY2018	uthr	Impairment Of Investments In Privately Held Companies ImpairmentOfInvestmentsInPrivatelyHeldCompanies	53500000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	45300000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	22600000	USD
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-46500000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	638900000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-165000000.0	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	758900000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	124100000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-60500000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	169700000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	514800000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-104500000	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	589200000	USD
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	11.65
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.39
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	13.54
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	11.54
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.39
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	13.39
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44200000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43800000	shares
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43500000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44600000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43800000	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44000000.0	shares
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-104500000	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	589200000	USD
CY2020	us-gaap	Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax	-8000000.0	USD
CY2019	us-gaap	Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax	-10600000	USD
CY2018	us-gaap	Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax	10700000	USD
CY2020	uthr	Other Comprehensive Income Loss Amortization Gain Loss And Net Prior Service Costs Credit Arising During Period Net Of Tax OtherComprehensiveIncomeLossAmortizationGainLossAndNetPriorServiceCostsCreditArisingDuringPeriodNetOfTax	1300000	USD
CY2019	uthr	Other Comprehensive Income Loss Amortization Gain Loss And Net Prior Service Costs Credit Arising During Period Net Of Tax OtherComprehensiveIncomeLossAmortizationGainLossAndNetPriorServiceCostsCreditArisingDuringPeriodNetOfTax	-1700000	USD
CY2018	uthr	Other Comprehensive Income Loss Amortization Gain Loss And Net Prior Service Costs Credit Arising During Period Net Of Tax OtherComprehensiveIncomeLossAmortizationGainLossAndNetPriorServiceCostsCreditArisingDuringPeriodNetOfTax	1400000	USD
CY2020	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	6700000	USD
CY2019	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	12300000	USD
CY2018	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	-12100000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	6700000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	6000000.0	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-400000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-6300000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	11700000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	514800000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-110800000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	600900000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	2101800000	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	589200000	USD
CY2018	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-400000	USD
CY2018	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	-12100000	USD
CY2018	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3900000	USD
CY2018	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	100000	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	15600000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	66500000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	2788600000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-104500000	USD
CY2019	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	6000000.0	USD
CY2019	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	12300000	USD
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	4100000	USD
CY2019	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2100000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9900000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	85100000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	10800000	USD
CY2019	uthr	Deconsolidation Of Variable Interest Entity DeconsolidationOfVariableInterestEntity	-100000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	2780400000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	514800000	USD
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	6700000	USD
CY2020	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	6700000	USD
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	4700000	USD
CY2020	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	3700000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	33800000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	66000000.0	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	3395200000	USD
CY2019Q2	uthr	Temporary Equity Amountof Common Stock Subjectto Repurchase TemporaryEquityAmountofCommonStockSubjecttoRepurchase	10800000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	514800000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-104500000	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	589200000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	49900000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	45900000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	35900000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	163800000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	45400000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	-26400000	USD
CY2020	uthr	Impairment Of Investments In Privately Held Companies ImpairmentOfInvestmentsInPrivatelyHeldCompanies	9100000	USD
CY2019	uthr	Impairment Of Investments In Privately Held Companies ImpairmentOfInvestmentsInPrivatelyHeldCompanies	0	USD
CY2018	uthr	Impairment Of Investments In Privately Held Companies ImpairmentOfInvestmentsInPrivatelyHeldCompanies	53500000	USD
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	5400000	USD
CY2019	us-gaap	Asset Impairment Charges AssetImpairmentCharges	17200000	USD
CY2018	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	47000000.0	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	29700000	USD
CY2018	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1800000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6000000.0	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-121400000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-10300000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-24400000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-12900000	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-9300000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	38600000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-16300000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-11000000.0	USD
CY2020	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-16800000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	201900000	USD
CY2018	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-4700000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	755700000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-206600000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	778400000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	59300000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	83700000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	184400000	USD
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2400000	USD
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2018	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2020	uthr	Advance Payment Related To Property Plant And Equipment AdvancePaymentRelatedToPropertyPlantAndEquipment	0	USD
CY2019	uthr	Advance Payment Related To Property Plant And Equipment AdvancePaymentRelatedToPropertyPlantAndEquipment	0	USD
CY2018	uthr	Advance Payment Related To Property Plant And Equipment AdvancePaymentRelatedToPropertyPlantAndEquipment	46000000.0	USD
CY2020	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	0	USD
CY2019	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	0	USD
CY2018	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	99300000	USD
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	0	USD
CY2019	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	39700000	USD
CY2018	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	88600000	USD
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	2308800000	USD
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1271500000	USD
CY2018	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	762700000	USD
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	1523400000	USD
CY2019	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	799200000	USD
CY2018	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	265900000	USD
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	76500000	USD
CY2019	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	180900000	USD
CY2018	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	46400000	USD
CY2020	us-gaap	Proceeds From Sale Of Trading Securities Heldforinvestment ProceedsFromSaleOfTradingSecuritiesHeldforinvestment	27300000	USD
CY2019	us-gaap	Proceeds From Sale Of Trading Securities Heldforinvestment ProceedsFromSaleOfTradingSecuritiesHeldforinvestment	20500000	USD
CY2018	us-gaap	Proceeds From Sale Of Trading Securities Heldforinvestment ProceedsFromSaleOfTradingSecuritiesHeldforinvestment	0	USD
CY2020	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	0	USD
CY2019	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	8000000.0	USD
CY2018	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	5000000.0	USD
CY2020	uthr	Decrease In Cash Due To Deconsolidation Of Variable Interest Entity DecreaseInCashDueToDeconsolidationOfVariableInterestEntity	0	USD
CY2019	uthr	Decrease In Cash Due To Deconsolidation Of Variable Interest Entity DecreaseInCashDueToDeconsolidationOfVariableInterestEntity	12500000	USD
CY2018	uthr	Decrease In Cash Due To Deconsolidation Of Variable Interest Entity DecreaseInCashDueToDeconsolidationOfVariableInterestEntity	0	USD
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2019	uthr	Decrease In Net Sales Revenue DecreaseInNetSalesRevenue	2300000	USD
CY2018	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	124100000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-738500000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-335400000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-820600000	USD
CY2020	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	USD
CY2019	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	800000000.0	USD
CY2018	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	250000000.0	USD
CY2020	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	50000000.0	USD
CY2019	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	200000000.0	USD
CY2018	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	250000000.0	USD
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1700000	USD
CY2019	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	700000	USD
CY2018	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	13200000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	33800000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9900000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	15600000	USD
CY2020	uthr	Increase In Net Product Sales IncreaseInNetProductSales	500000	USD
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	4700000	USD
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	4100000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	738400000	USD
CY2018	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	3900000	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3700000	USD
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2100000	USD
CY2018	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-16900000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	611200000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6300000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	300000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	69200000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-35900000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	738400000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	669200000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	705100000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	738700000	USD
CY2020	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	669200000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	20700000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	41000000.0	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	9400000	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	92800000	USD
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	120200000	USD
CY2018	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	102700000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3500000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	54500000	USD
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	11500000	USD
CY2020	us-gaap	Nature Of Operations NatureOfOperations	Organization and Business Description<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We have approval from the U.S. Food and Drug Administration (</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">FDA</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) to market the following therapies: Remodulin</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (treprostinil) Injection (</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Remodulin</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), Tyvaso</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (treprostinil) Inhalation Solution (</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Tyvaso</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), Orenitram</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (treprostinil) Extended-Release Tablets (</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Orenitram</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), Unituxin</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (dinutuximab) Injection (</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Unituxin</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), and Adcirca</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (tadalafil) Tablets (</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Adcirca</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">). Our only significant revenues outside the United States are derived from sales of Remodulin in Europe.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As used in these notes to our consolidated financial statements, unless the context otherwise requires, the terms “</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">we</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">”, “</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">us</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">”, “</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">our</span><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">”, and similar terms refer to United Therapeutics Corporation and its consolidated subsidiaries.</span></div>
CY2020Q4	us-gaap	Goodwill Goodwill	28000000.0	USD
CY2019Q4	us-gaap	Goodwill Gross GoodwillGross	28000000.0	USD
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'DIN Regular',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'DIN Regular',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The preparation of our consolidated financial statements in accordance with GAAP requires our management to make estimates and assumptions that affect reported amounts of assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. We base our estimates on assumptions regarding historical experience, currently available information, and anticipated developments that we believe are reasonable and appropriate. However, because the use of estimates involves an inherent degree of uncertainty, actual results could differ from those estimates. Estimates are used for, but not limited to, revenue recognition, share-based compensation, determining the fair value of assets acquired and liabilities assumed in business combinations, marketable investments, fair value measurements (including those related to contingent consideration), inventory reserves, investments in privately-held companies, income taxes, goodwill and other intangible assets, and obligations related to our Supplemental Executive Retirement Plan.</span></div>
CY2020Q4	us-gaap	Goodwill Gross GoodwillGross	28000000.0	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	18400000	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	21100000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	29500000	USD
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	29100000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	38600000	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	43200000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	86500000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	93400000	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2019Q4	us-gaap	Goodwill Goodwill	28000000.0	USD
CY2020Q4	uthr	Goodwill And Other Intangibles Assets Gross GoodwillAndOtherIntangiblesAssetsGross	163600000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5500000	USD
CY2020Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	158100000	USD
CY2019Q4	uthr	Goodwill And Other Intangibles Assets Gross GoodwillAndOtherIntangiblesAssetsGross	163600000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5300000	USD
CY2019Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	158300000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	200000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	200000	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1040900000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1007900000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	309300000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	269400000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	731600000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	738500000	USD
CY2020	us-gaap	Depreciation Depreciation	49700000	USD
CY2019	us-gaap	Depreciation Depreciation	45700000	USD
CY2018	us-gaap	Depreciation Depreciation	35800000	USD
CY2020	uthr	Number Of Disclosed Commercially Approved Products NumberOfDisclosedCommerciallyApprovedProducts	5	product
CY2018	uthr	Increase In Net Product Sales IncreaseInNetProductSales	8800000	USD
CY2018Q4	uthr	Reversal Of Estimated Liability Rebates ReversalOfEstimatedLiabilityRebates	13600000	USD
CY2020	uthr	Rebates And Chargebacks Maximum Eligible Payment Period RebatesAndChargebacksMaximumEligiblePaymentPeriod	P6M
CY2020Q4	uthr	Accrued Rebates And Chargebacks AccruedRebatesAndChargebacks	60700000	USD
CY2019Q4	uthr	Accrued Rebates And Chargebacks AccruedRebatesAndChargebacks	51700000	USD
CY2020	uthr	Revenue Deduction Rebates And Chargebacks RevenueDeductionRebatesAndChargebacks	182000000.0	USD
CY2019	uthr	Revenue Deduction Rebates And Chargebacks RevenueDeductionRebatesAndChargebacks	178700000	USD
CY2018	uthr	Revenue Deduction Rebates And Chargebacks RevenueDeductionRebatesAndChargebacks	223700000	USD
CY2020	uthr	Prompt Pay Discount Maximum Eligible Payment Period PromptPayDiscountMaximumEligiblePaymentPeriod	P30D
CY2020	uthr	Expiration Period For Right To Return Product ExpirationPeriodForRightToReturnProduct	P12M
CY2020	uthr	Allowance For Product Returns AllowanceForProductReturns	0	USD
CY2019	uthr	Decrease In Allowance For Product Returns DecreaseInAllowanceForProductReturns	6200000	USD
CY2018	uthr	Increase In Allowance For Product Returns IncreaseInAllowanceForProductReturns	17500000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	13000000.0	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	100000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	2246500000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	2233600000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	2246500000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1447600000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4600000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	200000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1452000000.0	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1452000000.0	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis	1093100000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue	1096900000	USD
CY2020Q4	uthr	Available For Sale Securities Debt Maturities Rolling Year One Through Three Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughThreeAmortizedCostBasis	1140500000	USD
CY2020Q4	uthr	Available For Sale Securities Debt Maturities Rolling Year One Through Year Three Fair Value AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughYearThreeFairValue	1149600000	USD
CY2020Q4	uthr	Contractual Maturities Of Available For Sale Debt Securities Amortized Cost Basis ContractualMaturitiesOfAvailableForSaleDebtSecuritiesAmortizedCostBasis	2233600000	USD
CY2020Q4	uthr	Contractual Maturities Of Available For Sale Securities Debt Securities ContractualMaturitiesOfAvailableForSaleSecuritiesDebtSecurities	2246500000	USD
CY2020	us-gaap	Proceeds From Sale Of Trading Securities Heldforinvestment ProceedsFromSaleOfTradingSecuritiesHeldforinvestment	27300000	USD
CY2019	us-gaap	Proceeds From Sale Of Trading Securities Heldforinvestment ProceedsFromSaleOfTradingSecuritiesHeldforinvestment	20500000	USD
CY2018	us-gaap	Proceeds From Sale Of Trading Securities Heldforinvestment ProceedsFromSaleOfTradingSecuritiesHeldforinvestment	0	USD
CY2020	uthr	Impairment Of Investments In Privately Held Companies ImpairmentOfInvestmentsInPrivatelyHeldCompanies	9100000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4100000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9900000	USD
CY2020Q4	uthr	Accrued Sales Related Royalties Rebates And Fees Current AccruedSalesRelatedRoyaltiesRebatesAndFeesCurrent	84500000	USD
CY2019Q4	uthr	Accrued Sales Related Royalties Rebates And Fees Current AccruedSalesRelatedRoyaltiesRebatesAndFeesCurrent	71500000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	47900000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	43400000	USD
CY2020Q4	uthr	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	27800000	USD
CY2019Q4	uthr	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	16300000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	22700000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7300000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	182900000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	138500000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	187000000.0	USD
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	148400000	USD
CY2019Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	250000000.0	USD
CY2020Q4	uthr	Number Of Equity Incentive Plans NumberOfEquityIncentivePlans	2	plan
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	163800000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	45400000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	-26400000	USD
CY2020	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	1000000.0	USD
CY2019	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	700000	USD
CY2018	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	700000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	514800000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-104500000	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	589200000	USD
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44200000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43800000	shares
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43500000	shares
CY2020	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	400000	shares
CY2019	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2018	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	500000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44600000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43800000	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44000000.0	shares
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	11.65
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.39
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	13.54
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	11.54
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.39
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	13.39
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6600000	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7200000	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4700000	shares
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	114600000	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	63100000	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	136600000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	20000000.0	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	9400000	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	17400000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	134600000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	72500000	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	154000000.0	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1600000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-120100000	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	12700000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-12100000	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-12900000	USD
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	3000000.0	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-10500000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-133000000.0	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	15700000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	124100000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-60500000	USD
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	3500000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	169700000	USD
CY2020	uthr	Effective Income Tax Rate Reconciliation Deconsolidation Of Vie EffectiveIncomeTaxRateReconciliationDeconsolidationOfVie	0	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	134200000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-34700000	USD
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	159400000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	24000000.0	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	21300000	USD
CY2018	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	16000000.0	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	11500000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	6300000	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	2100000	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	7000000.0	USD
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	4900000	USD
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-3100000	USD
CY2018	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	15700000	USD
CY2020	uthr	Effective Income Tax Rate Reconciliation Uncertain Tax Positions EffectiveIncomeTaxRateReconciliationUncertainTaxPositions	4800000	USD
CY2019	uthr	Effective Income Tax Rate Reconciliation Uncertain Tax Positions EffectiveIncomeTaxRateReconciliationUncertainTaxPositions	-300000	USD
CY2018	uthr	Effective Income Tax Rate Reconciliation Uncertain Tax Positions EffectiveIncomeTaxRateReconciliationUncertainTaxPositions	0	USD
CY2020	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-4100000	USD
CY2019	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-1600000	USD
CY2018	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	600000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-3100000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-5700000	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	11200000	USD
CY2020	us-gaap	Income Tax Reconciliation Deductions Extraterritorial Income Exclusion IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion	2200000	USD
CY2019	us-gaap	Income Tax Reconciliation Deductions Extraterritorial Income Exclusion IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion	3300000	USD
CY2018	us-gaap	Income Tax Reconciliation Deductions Extraterritorial Income Exclusion IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion	3300000	USD
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	0	USD
CY2019	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	5100000	USD
CY2018	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	0	USD
CY2019	uthr	Effective Income Tax Rate Reconciliation Deconsolidation Of Vie EffectiveIncomeTaxRateReconciliationDeconsolidationOfVie	1900000	USD
CY2018	uthr	Effective Income Tax Rate Reconciliation Deconsolidation Of Vie EffectiveIncomeTaxRateReconciliationDeconsolidationOfVie	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	124100000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-60500000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	169700000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	176000000.0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	187900000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	73100000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	56100000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	18800000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	17600000	USD
CY2020Q4	uthr	Deferred Tax Assets Supplemental Executive Retirement Plan DeferredTaxAssetsSupplementalExecutiveRetirementPlan	10900000	USD
CY2019Q4	uthr	Deferred Tax Assets Supplemental Executive Retirement Plan DeferredTaxAssetsSupplementalExecutiveRetirementPlan	10100000	USD
CY2018	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4200000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9700000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8800000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	7400000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	19500000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	5600000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	6500000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	301500000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	306500000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	35500000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	36600000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	266000000.0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	269900000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	26100000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	38700000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	1300000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	1200000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	27400000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	3800000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	39900000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	238600000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	230000000.0	USD
CY2020Q4	uthr	Unrecognized Tax Benefits Including Interest And Penalties UnrecognizedTaxBenefitsIncludingInterestAndPenalties	4900000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	400000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	300000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	500000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	500000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	500000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	700000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4500000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	500000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4500000	USD
CY2020Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease	0.0400
CY2019Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease	0.0400
CY2020	uthr	Defined Benefit Plan Benefit Obligation Increase Decrease For Discount Rate DefinedBenefitPlanBenefitObligationIncreaseDecreaseForDiscountRate	3200000	USD
CY2020	us-gaap	Defined Benefit Plan Benefit Obligation Period Increase Decrease DefinedBenefitPlanBenefitObligationPeriodIncreaseDecrease	5300000	USD
CY2020	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.40
CY2020	uthr	Defined Contribution Plan Vesting Of Matching Contribution Service Period DefinedContributionPlanVestingOfMatchingContributionServicePeriod	P3Y
CY2020	uthr	Defined Contribution Plan Annual Increments Vesting Period DefinedContributionPlanAnnualIncrementsVestingPeriod	P3Y
CY2020	uthr	Defined Contribution Plan Vesting Of Matching Contribution Service Period DefinedContributionPlanVestingOfMatchingContributionServicePeriod	P3Y
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2900000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2600000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2200000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1800000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1900000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	8600000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	20000000.0	USD
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1483300000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	108100000	USD
CY2020	uthr	Gross Profit Excluding Other Revenue GrossProfitExcludingOtherRevenue	1375200000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1448800000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	117600000	USD
CY2019	uthr	Gross Profit Excluding Other Revenue GrossProfitExcludingOtherRevenue	1331200000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1627800000	USD
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	198700000	USD
CY2018	uthr	Gross Profit Excluding Other Revenue GrossProfitExcludingOtherRevenue	1429100000	USD
CY2020	us-gaap	Revenues Revenues	1483300000	USD
CY2019	us-gaap	Revenues Revenues	1448800000	USD
CY2018	us-gaap	Revenues Revenues	1627800000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	731600000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	738500000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	699700000	USD
CY2019Q1	uthr	Upfront Payment UpfrontPayment	800000000.0	USD

Files In Submission

Name	View Source	Status
0001082554-21-000008-index-headers.html	Edgar Link	pending
0001082554-21-000008-index.html	Edgar Link	pending
0001082554-21-000008.txt	Edgar Link	pending
0001082554-21-000008-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
uthr-20201231.htm	Edgar Link	pending
uthr-20201231.xsd	Edgar Link	pending
uthr-20201231_cal.xml	Edgar Link	unprocessable
uthr-20201231_def.xml	Edgar Link	unprocessable
uthr-20201231_g1.jpg	Edgar Link	pending
uthr-20201231_htm.xml	Edgar Link	completed
uthr-20201231_lab.xml	Edgar Link	unprocessable
uthr-20201231_pre.xml	Edgar Link	unprocessable
uthrexh211231202010k.htm	Edgar Link	pending
uthrexh23112312020.htm	Edgar Link	pending
uthrexh3111231202010k.htm	Edgar Link	pending
uthrexh3121231202010k.htm	Edgar Link	pending
uthrexh3211231202010k.htm	Edgar Link	pending
uthrexh3221231202010k.htm	Edgar Link	pending
uthrexh421231202010k.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$UTHR
UNITED THERAPEUTICS Corp Stock $uthr

2020 Form 10-K Financial Statement

#000108255421000008 Filed on February 24, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$UTHR UNITED THERAPEUTICS Corp Stock $uthr

2020 Form 10-K Financial Statement

#000108255421000008 Filed on February 24, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$UTHR
UNITED THERAPEUTICS Corp Stock $uthr